Table of Contents
Tdap protects against tetanus, diphtheria and whooping cough. Adults usually get it as a booster, after a wound or during pregnancy. A study published in July 2026 in the journal Vaccine found a possible link between Tdap and Guillain-Barré syndrome (GBS), a rare disorder that attacks the nerves.
What Is Guillain-Barré Syndrome (GBS) after a Tdap vaccine?
GBS damages the protective coating of the nerves, which slows or blocks signals between the brain and the muscles. Early signs can include pins and needles in the hands or feet, leg weakness, trouble climbing stairs, and in some cases facial weakness or difficulty swallowing. Anyone with spreading weakness after a vaccine should get medical care quickly.
How researchers studied Tdap and Guillaine-Barre Syndrome
Researchers from the Harvard Pilgrim Health Care Institute and the CDC used the Vaccine Safety Datalink, which links vaccination and medical records from large U.S. health systems. Their starting point was the illness, not the vaccine. They gathered 2,584 adult GBS diagnoses from 10 health systems between 2017 and 2023, then looked back 12 weeks to see which vaccines each person had received.
For Tdap, that look-back covered more than 4.6 million doses. If GBS had nothing to do with Tdap, diagnoses would be spread evenly across the 12 weeks after a shot. Instead, they clustered in the early weeks after vaccination.
Tdap was one of the vaccines that produced a statistically significant signal for GBS. During the 21 days after a Tdap shot, GBS diagnoses happened at about two and a half times the expected rate. The researchers estimated about 2 extra GBS cases for every 1 million Tdap doses.
When does GBS start after a tetanus diphtheria pertussis vaccine?
The timing of GBS after Tdap closely matched the timing after flu shots. For both vaccines, the extra GBS cases happened in the first three weeks after the shot. By weeks four through six, the rate of GBS diagnoses had returned to about normal.
That parallel matters. GBS after a flu shot is already a recognized vaccine injury in the VICP when symptoms begin 3 to 42 days after the shot. The new study shows a very similar pattern after Tdap vaccination.
Is GBS after a Tdap vaccine a covered vaccine injury?
Tdap is one of the vaccines covered by the National Vaccine Injury Compensation Program (VICP), whether it was given as a routine booster, after a wound, or during pregnancy.
People who develop GBS after Tdap can be compensated, but they need to show that the vaccine more likely than not caused their illness. That usually means getting a medical expert’s explanation of how Tdap can trigger GBS, medical records tying the shot to the illness, and a timeline that fits.
What the Tdap GBS study means in a vaccine injury claim
The new study may help Tdap GBS claims in the VICP. It adds large-scale data from the CDC’s own vaccine safety system pointing to a link between Tdap and GBS. The strength of a Tdap GBS claim depends on the details of each case. To be eligible for a vaccine injury claim, the injury usually must last more than six months or require a hospital stay with surgery. Awards can cover medical expenses, lost income and pain and suffering. Legal fees are paid by the Vaccine Court, and not deducted from your award.
Talk With a Vaccine Injury Lawyer About GBS After Tdap
GBS cases are a core part of our legal work in the Vaccine Injury Compensation Program. The attorneys at mctlaw have won hundreds of millions of dollars for our GBS clients in the VICP. If you got GBS after a Tdap vaccine, the vaccine injury legal team at mctlaw can review your case for free with no pressure or obligation.
Over the past 25 years, mctlaw has represented more than 1,000 successful VICP claims for clients across the United States. Our attorneys have recovered hundreds of millions of dollars for people injured by vaccines and their families, including the highest single award in vaccine court history, and a $101 million VICP award.
Contact mctlaw at 888.952.5242 for a free vaccine injury case evaluation.
Yih WK et al., Vaccine, 2026: tree-based scan statistics and GBS in the Vaccine Safety Datalink
CDC presentation to ACIP, October 2024: PCV20 safety, including GBS findings
